BioSpace News Archive

Exicure, Inc. previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang Kim as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company’s board of directors.

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and other diseases with unmet medical need, announced the results of the votes of its Combined Shareholders’ Meeting.

Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved INPEFA™, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with.

Japan Association for Cellular Agriculture, a Japan-based non-profit research institute hosted the inaugural meeting in Tokyo, in response to Japanese Prime Minister Fumio Kishida’s announcement in February 2023 of the intention to develop the domestic cultivated food industry.

The Masimo Corporation Board of Directors issued a letter to stockholders in connection with its definitive proxy materials filed on May 24, 2023, and the Company’s Annual Meeting of Stockholders to be held on June 26, 2023.

Senseonics Holdings, Inc. announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.

Exact Sciences Corp. announced that it will present 15 abstracts at the American Society of Clinical Oncology® Annual Meeting 2023, June 2-6, in Chicago, Illinois.

Foundation Medicine, Inc., announced that the company and its collaborators will present 21 abstracts demonstrating the value of high-quality tumor profiling tests to inform cancer care at the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6 in Chicago.

On 26th May 2023, an Annual General Meeting was held in Immunovia AB, 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund.

Lyra Therapeutics, Inc. announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses.